Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19‑positive hepatocellular carcinoma

Lee,Chao‑Wei; Lin,Sey‑En; Tsai,Hsin‑I; Su,Po‑Jung; Hsieh,Chia‑Hsun; Kuo,Yung‑Chia; Sung,Chang‑Mu; Lin,Cheng‑Yu; Tsai,Chi‑Neu; Yu,Ming‑Chin

doi:10.3892/ol.2017.7320

Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19‑positive hepatocellular carcinoma

Authors:
- Chao‑Wei Lee
- Sey‑En Lin
- Hsin‑I Tsai
- Po‑Jung Su
- Chia‑Hsun Hsieh
- Yung‑Chia Kuo
- Chang‑Mu Sung
- Cheng‑Yu Lin
- Chi‑Neu Tsai
- Ming‑Chin Yu
View Affiliations

Affiliations: Department of Surgery, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan, R.O.C., Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei 11696, Taiwan, R.O.C., College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan, R.O.C., Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan, R.O.C., Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan 33302, Taiwan, R.O.C.
Published online on: November 1, 2017 https://doi.org/10.3892/ol.2017.7320
Pages: 559-567

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A previous study demonstrated that cytokeratin 19 (CK19) expression in hepatocellular carcinoma (HCC) is an indicator of HCC invasiveness, including lymph node metastasis (LNM), tumor infiltration/non‑encapsulation and poor prognosis. The exact mechanism by which CK19 expression results in poor prognosis remains unclear. Through the use of an Affymetrix U133A oligonucleotide microarray [20 patients with hepatitis B virus (HBV)‑HCC], it was demonstrated that cadherin 17 (CDH17) significantly correlated with CK19 expression (R2, 0.867; P<0.001) in HBV‑HCC. Immunohistochemical analysis (114 patients with HBV‑HCC) also demonstrated a significant correlation between CK19 and CDH17 expressions in primary tumor tissue (R2, 0.414; P<0.001). In addition, CK19 and CDH17 expressions levels revealed a significant association with LNM (P<0.001). Cox regression multivariate analysis demonstrated that indocyanine green retention at 15 min >10% and CDH17 expression were independent prognostic factors for disease free survival (P=0.010 and 0.002, respectively). In vitro studies showed that epidermal growth factor can induce the expression of both CK19 and CDH17, and CDH17 in turn can enhance the expression of CK19 in HCC. In summary, this study demonstrated that the early recurrence and poor prognosis of CK19(+) HCC may be due to the expression of CDH17, a gene known to be associated with vascular invasion, tumor metastasis, and advanced tumor stage of HCC. Thus, novel therapeutics by targeting CDH17 may be beneficial for CK19(+) HCC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Sartorius K, Sartorius B, Aldous C, Govender PS and Madiba TE: Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiol. 39:284–290. 2015. View Article : Google Scholar : PubMed/NCBI
3	Ministry of Health and Welfare. Executive Yuan, R.O.C: Report of leading cancer-related death in 2014. 2015.
4	Lee CW, Kuo WL, Yu MC, Chen TC, Tsai CN, Lee WC and Chen MF: The expression of cytokeratin 19 in lymph nodes was a poor prognostic factor for hepatocellular carcinoma after hepatic resection. World J Surg Oncol. 11:1362013. View Article : Google Scholar : PubMed/NCBI
5	Corcelle V, Stieger B, Gjinovci A, Wollheim CB and Gauthier BR: Characterization of two distinct liver progenitor cell subpopulations of hematopoietic and hepatic origins. Exp Cell Res. 312:2826–2836. 2006. View Article : Google Scholar : PubMed/NCBI
6	Yamamoto T, Uenishi T, Ogawa M, Ichikawa T, Hai S, Sakabe K, Tanaka S, Kato H, Mikami S, Ikebe T, et al: Immunohistologic attempt to find carcinogenesis from hepatic progenitor cell in hepatocellular carcinoma. Dig Surg. 22:364–370. 2005. View Article : Google Scholar : PubMed/NCBI
7	Yoneda N, Sato Y, Kitao A, Ikeda H, Sawada-Kitamura S, Miyakoshi M, Harada K, Sasaki M, Matsui O and Nakanuma Y: Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma. Lab Invest. 91:262–272. 2011. View Article : Google Scholar : PubMed/NCBI
8	Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B and Llovet JM: Molecular classification and novel targets in hepatocellular carcinoma: Recent advancements. Semin Liver Dis. 30:35–51. 2010. View Article : Google Scholar : PubMed/NCBI
9	Uenishi T, Hirohashi K, Shuto T, Kubo S, Tanaka H, Sakata C, Ikebe T and Kinoshita H: The clinical significance of lymph node metastases in patients undergoing surgery for hepatocellular carcinoma. Surg Today. 30:892–895. 2000. View Article : Google Scholar : PubMed/NCBI
10	Chu KM, Lai EC, Al-Hadeedi S, Arcilla CE Jr, Lo CM, Liu CL, Fan ST and Wong J: Intrahepatic cholangiocarcinoma. World J Surg. 21:301–305; discussion 305–306. 1997. View Article : Google Scholar : PubMed/NCBI
11	Lee CW, Chan KM, Lee CF, Yu MC, Lee WC, Wu TJ and Chen MF: Hepatic resection for hepatocellular carcinoma with lymph node metastasis: Clinicopathological analysis and survival outcome. Asian J Surg. 34:53–62. 2011. View Article : Google Scholar : PubMed/NCBI
12	Ding ZB, Shi YH, Zhou J, Shi GM, Ke AW, Qiu SJ, Wang XY, Dai Z, Xu Y and Fan J: Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus-positive hepatocellular carcinoma. Cancer. 115:4753–4765. 2009. View Article : Google Scholar : PubMed/NCBI
13	Lee NP, Poon RT, Shek FH, Ng IO and Luk JM: Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. Biochim Biophys Acta. 1806:138–145. 2010.PubMed/NCBI
14	International Union Against Cancer (UICC), . TNM Classification of Malignant Tumours. Sobin LH, Gospodarowicz MK and Wittekind C: 7th. Wiley-Blackwell; Hoboken, NJ: 2009
15	Yu MC, Lee YS, Lin SE, Wu HY, Chen TC, Lee WC, Chen MF and Tsai CN: Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin. Ann Surg Oncol. 3 Suppl 19:S455–S463. 2012. View Article : Google Scholar
16	Libbrecht L, Desmet V, Van Damme B and Roskams T: The immunohistochemical phenotype of dysplastic foci in human liver: Correlation with putative progenitor cells. J Hepatol. 33:76–84. 2000. View Article : Google Scholar : PubMed/NCBI
17	Takano M, Shimada K, Fujii T, Morita K, Takeda M, Nakajima Y, Nonomura A, Konishi N and Obayashi C: Keratin 19 as a key molecule in progression of human hepatocellular carcinomas through invasion and angiogenesis. BMC Cancer. 16:9032016. View Article : Google Scholar : PubMed/NCBI
18	Qiu HB, Zhang LY, Ren C, Zeng ZL, Wu WJ, Luo HY, Zhou ZW and Xu RH: Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/β-catenin signaling. PLoS One. 8:e569592013. View Article : Google Scholar : PubMed/NCBI
19	Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, et al: Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology. 50:1453–1463. 2009. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Shek FH, Wong KF, Liu LX, Zhang XQ, Yuan Y, Khin E, Hu MY, Wang JH, Poon RT, et al: Anti-cadherin-17 antibody modulates beta-catenin signaling and tumorigenicity of hepatocellular carcinoma. PLoS One. 8:e723862013. View Article : Google Scholar : PubMed/NCBI
21	Yamamoto Y, Ikoma H, Morimura R, Konishi H, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y, Kubota T, Nakanishi M, et al: Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. World J Gastroenterol. 21:1207–1215. 2015. View Article : Google Scholar : PubMed/NCBI
22	Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK and Batra SK: Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:15–31. 2012. View Article : Google Scholar : PubMed/NCBI
23	Blobel CP: ADAMs: Key components in EGFR signalling and development. Nat Rev Mol Cell Biol. 6:32–43. 2005. View Article : Google Scholar : PubMed/NCBI